Skip to main content
OpenTrials
Completed

NCT Number: NCT00299104

A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis

This is a phase III, randomized, controlled, double-blind, parallel group, international study in approximately 750 patients with active Rheumatoid Arthritis (RA) who are naive to Methotrexate (MTX) therapy. Rheumatoid Factor (RF)-positive and RF-negative patients will be enrolled and will be allocated equally between 3 treatment arms.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients 18-80 years of age
  • RA for ≥ 2 months;
  • Receiving outpatient treatment
  • Patients naive to, and considered to be candidates for, methotrexate treatment

Exclusion criteria

  • Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA
  • Inflammatory joint disease other than RA, or other systemic autoimmune disorder
  • Diagnosis of juvenile rheumatoid arthritis, or RA before the age of 16
  • Surgery within 12 weeks of study
  • Previous treatment with any approved or investigational biologic agent for RA, an anti-alpha4-integrin antibody or co-stimulation modulator, or cell-depleting therapy
  • Concurrent treatment with any biologic agent or DMARD other than methotrexate

Treatment and study plan

Folate

Drug

Intravenous repeating dose

methotrexate

Drug

Oral or parenteral repeating dose

methylprednisolone

Drug

Intravenous repeating dose

Placebo

Drug

Intravenous repeating dose

Rituximab

Drug

Intravenous repeating dose

Primary outcomes

  1. Change From Baseline in Modified Total Sharp Score (mTSS) From Screening at Week 52

    Time frame: Baseline and week 52

    Rate of progression in structural joint damage (PJD) by change in Total Modified Sharp Score (TMSS) from screening to Week 52 in the modified intent-to-treat (MITT) population. TMSS is the sum of the erosion score (ES) and the joint space narrowing (JSN) score and has a range of 0 to 398. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. The JSN is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change and higher scores represent a worsening of joint erosions and joint space narrowing.

Secondary outcomes

  1. Change From Baseline in Modified Sharp Erosion Score at Week 52

    Time frame: Baseline and week 52

    Rate of progression in structural joint damage (PJD) by change in modified Sharp erosion score from screening to Week 52. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. A score of 0 would indicate no change and higher scores represent a worsening of joint erosions.

  2. Percentage of Patients Without Radiographic Progression at Week 52

    Time frame: Baseline, Week 52

    Percentage of patients without radiographic progression at Week 52, defined as change in total modified Sharp score (TMSS) <= 0. TMSS is the sum of the erosion score (ES) and the joint space narrowing (JSN) score and has a range of 0 to 398. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. The JSN is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change.

  3. Percentage of Patients Without Radiographic Progression in Total Erosion Score at Week 52

    Time frame: Baseline, Week 52

    No radiographic progression is defined as a change in the total erosion score at Week 52 of less than or equal to zero.

  4. Change From Baseline in Modified Joint Space Narrowing (JSN) Score at Week 52

    Time frame: Baseline and week 52

    Rate of progression in structural joint damage (PJD) by change in modified joint space narrowing (JSN) from screening to Week 52. The JSN is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing.

  5. Change From Baseline in the Modified Total Sharp Score at Week 24

    Time frame: Baseline, Week 24

    The modified total sharp score is the sum of the erosion score (ES) and the joint space narrowing (JSN) score and has a range of 0 to 398. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. The JSN is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change and higher scores represent a worsening of joint erosions and joint space narrowing.

  6. Change From Baseline in the Total Erosion Score at Week 24

    Time frame: Baseline, Week 24

    Total Erosion Score is determined by evaluation of fourteen sites in each wrist and hand and six joints in each foot using an eight-point scale from 0 (normal: no erosions) to 3.5 (Very severe; erosions of 100% of the articular surfaces. The Total Erosion Score at Week 24 - Total Erosion Score at baseline is calculated.

  7. Change From Baseline in Modified Joint Space Narrowing (JSN) Score at Week 24

    Time frame: Baseline, Week 24

    Joint Space Narrowing is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing.

  8. Percentage of Participants Without Radiographic Progression at Week 24

    Time frame: Baseline, Week 24

    Percentage of patients without radiographic progression at Week 24 defined as change in total modified Sharp score (TMSS) ≤ 0. TMSS is the sum of the erosion score (ES) and the joint space narrowing (JSN) score and has a range of 0 to 398. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. The JSN is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change.

  9. Percentage of Participants With American College of Rheumatology (ACR) ACR50 Response at Week 52

    Time frame: Week 52

    To achieve an ACR50 response requires at least a 50% improvement compared with baseline in both Total Joint Count and Swollen Joint Count, as well as a 50% improvement in three of five additional measurements from:

    • the physician's global assessment of disease activity
    • patient's global assessment of disease activity
    • patient's assessment of pain
    • HAQ-DI (Health Assessment Questionnaire disability index)
    • an acute phase reactant C-Reactive Protein (CRP). (If CRP was missing then Erythrocyte Sedimentation Rate (ESR) was used if available.)
  10. Change From Baseline in the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 52

    Time frame: Baseline, Week 52

    DAS28-ESR is calculated from the following formula:

    (0.56 * TJC) + (0.28 * SJC) + (0.70 * ln ESR) + (0.014 * GH) TJC = tender joint count, based on 28 joints SJC = swollen joint count, based on 28 joints ESR = erythrocyte sedimentation rate in mm/h GH = patient's global assessment of disease activity A DAS28-ESR score of 5.1 or above is considered to indicate high disease activity. Patients can also be defined as having low disease activity (DAS28-ESR ≤ 3.2) or remission (DAS28-ESR < 2.6).

  11. Percentage of Participants With American College of Rheumatology (ACR) ACR70 Response at Week 52

    Time frame: Baseline, Week 52

    To achieve an ACR70 response requires at least a 70% improvement compared with baseline in both Total Joint Count and Swollen Joint Count, as well as a 70% improvement in three of five additional measurements from:

    • the physician's global assessment of disease activity
    • patient's global assessment of disease activity
    • patient's assessment of pain
    • HAQ-DI (Health Assessment Questionnaire disability index)
    • an acute phase reactant C-Reactive Protein (CRP). (If CRP was missing then Erythrocyte Sedimentation Rate (ESR) was used if available.)
  12. Percentage of Participants With DAS28-ESR Remission at Week 52

    Time frame: Week 52

    The DAS28-4(ESR) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity (mm), and ESR. DAS28-4(ESR) scores range from 0 - 10.

    Remission is defined as achieving a DAS28-ESR score of less than 2.6

  13. Percentage of Participants With European League Against Rheumatism (EULAR) Good Response at Week 52

    Time frame: Baseline, Week 52

    European League Against Rheumatism (EULAR) criteria reflects an improvement in disease activity and an attainment of a lower degree of disease activity. A good response is defined as an improvement in the DAS28-ESR of > 1.2 compared with baseline, and attainment of a DAS28-ESR of < 3.2.

  14. The Percentage of Participants With Major Clinical Response at Week 52

    Time frame: Week 52

    Major clinical response is defined as a continuous six-month period of success by the ACR70.

    ACR70= 70% improvement compared with baseline in both Total Joint Count and Swollen Joint Count, as well as a 70% improvement in 3 of five additional measurements from:

    • the physician's global assessment of disease activity
    • patient's global assessment of disease activity
    • patient's assessment of pain
    • HAQ-DI (Health Assessment Questionnaire disability index)
    • an acute phase reactant C-Reactive Protein (CRP). (If CRP was missing then Erythrocyte Sedimentation Rate (ESR) was used if available.)
  15. Percentage of Participants With DAS28-ESR Low Disease Activity at Week 52

    Time frame: Week 52

    The DAS28-4(ESR) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity (mm), and ESR. DAS28-4(ESR) scores range from 0 - 10.

    Low disease activity is defined as achieving a DAS28-ESR score of less than or equal to 3.2

  16. Percentage of Participants With American College of Rheumatology (ACR) ACR20 Response at Week 52

    Time frame: Baseline, Week 52

    To achieve an ACR20 response requires at least a 20% improvement compared with baseline in both Total Joint Count and Swollen Joint Count, as well as a 20% improvement in three of five additional measurements from:

    • the physician's global assessment of disease activity
    • patient's global assessment of disease activity
    • patient's assessment of pain
    • HAQ-DI (Health Assessment Questionnaire disability index)
    • an acute phase reactant C-Reactive Protein (CRP). (If CRP was missing then Erythrocyte Sedimentation Rate (ESR) was used if available.)
  17. Percentage of Participants With American College of Rheumatology (ACR) ACR90 Response at Week 52

    Time frame: Baseline, Week 52

    To achieve an ACR90 response requires at least a 90% improvement compared with baseline in both Total Joint Count and Swollen Joint Count, as well as a 90% improvement in three of five additional measurements from:

    • the physician's global assessment of disease activity
    • patient's global assessment of disease activity
    • patient's assessment of pain
    • HAQ-DI (Health Assessment Questionnaire disability index)
    • an acute phase reactant C-Reactive Protein (CRP). (If CRP was missing then Erythrocyte Sedimentation Rate (ESR) was used if available.)
  18. Change in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Score From Baseline at Week 52

    Time frame: Baseline, Week 52

    FACIT-F is a 13-item questionnaire. Patients scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the patient's response to the questions (with the exception of 2 negatively stated), the greater the patient's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the patient's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the patient's health status.

  19. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52

    Time frame: Baseline, Week 52

    The Stanford Health Assessment Questionnaire disability index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip,and common daily activities. Each domain has at least two component questions. There are four possible responses for each component ranging from 0(without any difficulty) to 4 (unable to do).HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. A negative change from baseline indicates improvement.

  20. Change From Baseline in the SF-36 Physical Health Component Summary Score at Week 52 and Week 104

    Time frame: Baseline, Week 52, Week 104

    The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.

    Means are adjusted for baseline value, Rheumatoid Factor status and region.

  21. Change From Baseline in the SF-36 Mental Health Component Summary Score at Week 52 and Week 104

    Time frame: Baseline, Weeks 52, Week 104

    The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.

    Means are adjusted for baseline value, Rheumatoid Factor status and region.

  22. Percentage of Participants With Categorical Change in Health Assessment Questionnaire- Disability Index (HAQ-DI) From Baseline at Week 52

    Time frame: Baseline, Week 52

    The Stanford Health Assessment Questionnaire disability index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Each domain has at least two component questions. There are four possible responses for each component on a scale of 0 (without difficulty) to 3 (unable to do). Higher scores=greater dysfunction.

    Improved:HAQ-DI score change <=-0.22 Unchanged:HAQ-DI score change -0.22 to 0.22 Worsened:HAQ score => 0.22

  23. Percentage of Patients With Minimally Clinically Important Difference (MCID) in the SF-36 Physical Health Component Score at Week 52

    Time frame: Baseline, Week 52

    MCID is defined as a change from baseline in SF-36 Physical Health Component Score of >5.42.

    SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.

  24. Percentage of Patients With Minimally Clinically Important Difference (MCID) in the SF-36 Mental Health Component Score at Week 52

    Time frame: Baseline, Week 52

    MCID is defined as a change from baseline in SF-36 Mental Health Component Score of >6.33.

    SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.

  25. Change From Baseline in the Modified Total Sharp Score at Week 104

    Time frame: Baseline, Week 104

    The modified total sharp score is the sum of the erosion score (ES) and the joint space narrowing (JSN) score and has a range of 0 to 398. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. The JSN is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change and higher scores represent a worsening of joint erosions and joint space narrowing.

  26. Change From Baseline in the Total Erosion Score at Week 104

    Time frame: Baseline, Week 104

    Total Erosion Score is determined by evaluation of fourteen sites in each wrist and hand and six joints in each foot using an eight-point scale from 0 (normal: no erosions) to 3.5 (Very severe; erosions of 100% of the articular surfaces. The change from the score at baseline to week 104 is calculated.

  27. Percentage of Participants Without Radiographic Progression at Week 104

    Time frame: Baseline, Week 104

    Percentage of patients without radiographic progression at Week 104, defined as change in total modified Sharp score (TMSS) ≤ 0. TMSS is the sum of the erosion score (ES) and the joint space narrowing (JSN) score and has a range of 0 to 398. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. The JSN is the sum of joint scores collected for 42 joints and has a range of 0 to 168. A score of 0 would indicate no change.

  28. Percentage of Participants Without Radiographic Progression in the Total Erosion Score at Week 104

    Time frame: Week 104

    Total Erosion Score is determined by evaluation of fourteen sites in each wrist and hand and six joints in each foot using an eight-point scale from 0 (normal: no erosions) to 3.5 (Very severe; erosions of 100% of the articular surfaces. The score at baseline is compared to the score at week 104.

    No progression is defined as a change from score at screening to week 104 ≤0.

  29. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 104

    Time frame: Baseline, Week 104

    The Stanford Health Assessment Questionnaire disability index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Each domain has at least two component questions. There are four possible responses for each component ranging from 0(without any difficulty) to 4 (unable to do). HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. A negative change from baseline indicates improvement.

Sponsors and collaborators

Lead sponsor

Genentech, Inc.

Industry

Collaborators

  • Hoffmann-La Roche

Registry information

Official study title

A Randomized, Phase 3, Controlled, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate (MTX) Compared to MTX Alone, in Methotrexate-Naive Patients With Active Rheumatoid Arthritis

Acronym: IMAGE

Important dates

Study start
2006
Primary completion
2008
Study completion
2013
First posted
Mar 6, 2006
Registry last updated
Jul 28, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.